E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Moderate to severe plaque type psoriasis |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Skin and Connective Tissue Diseases [C17] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10071117 |
E.1.2 | Term | Plaque psoriasis |
E.1.2 | System Organ Class | 100000004858 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To demonstrate that the combination of Secukinumab with lifestyle intervention results in higher psoriasis treatment efficacy compared to Secukinumab alone in psoriasis patients with concomitant metabolic syndrome. |
|
E.2.2 | Secondary objectives of the trial |
- To explore treatment efficacy of Secukinumab combined with lifestyle intervention in comparison to Secukinumab alone.
- To evaluate the effect of Secukinumab combined with lifestyle intervention in comparison to Secukinumab alone on systemic inflammation.
- To evaluate the effect of Secukinumab combined with lifestyle intervention in comparison to Secukinumab alone on glucose metabolism.
- To evaluate the effect of Secukinumab combined with lifestyle intervention in comparison to Secukinumab alone on lipid metabolism.
- To evaluate the effect of Secukinumab combined with lifestyle intervention in comparison to Secukinumab alone on body weight.
- To evaluate the effect of Secukinumab combined with lifestyle intervention in comparison to Secukinumab alone on systolic and diastolic blood pressure.
- To evaluate the effect of Secukinumab combined with lifestyle intervention in comparison to Secukinumab alone on health-related quality of life and mental well-being. |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Biomarker substudy, incorporated within Amendment 2 of clinical study protocol Version 02, dated 5. Sept 2018.
A biomarker sub-study will be conducted during the core study in a subgroup of 100 patients (50 from each treatment arm) to explore the effect of Secukinumab (300 mg, 4-weekly s.c.) combined with lifestyle intervention in comparison to Secukinumab alone on biomarkers including but not limited to those linked to lipid, glucose, muscle and bone metabolism, liver fibrosis/steatosis, heart failure, as well as to inflammatory processes. At baseline (week 0), week 16 and week 28 the following markers will be assessed using fasting blood samples: Free fatty acid serum profile, sThy-1, adiponectin, leptin, insulin, HOMA-IR, proinsulin, IL-6, TNF-alpha, M30 assay, IL-1 beta, IL-1Ra, IL-18, IL-18bp, P1NP, CTX, RANKL, OPG, sclerostin, NT-proBNP, CD154, and a 30-panel multiplex inflammatory cytokine and chemokines panel.
The additional risks of participating in the biomarker sub-study are those of blood sampling. Blood sampling will occur at time points where standard blood sampling is scheduled as well, and will not require additional venipuncture. Participation in the sub-study does not negatively affect the overall risk-benefit ratio for participation in the study. Patients eligible for inclusion in the biomarker sub-study will be recruited at study sites participating in the biomarker sub-study. Written informed consent for the biomarker sub-study must be obtained before any assessment for the biomarker sub-study is performed.
Objective: To explore the effect of Secukinumab (300 mg, 4-weekly s.c.) combined with lifestyle intervention in comparison to Secukinumab alone on biomarkers including but not limited to those linked to lipid, glucose, muscle and bone metabolism, liver fibrosis/steatosis, heart injury, as well as to inflammatory processes in a subgroup of 100 patients (50 treated with secukinumab and lifestyle intervention and 50 treated with secukinumab alone)
Endpoint: At baseline (week 0), week 16 and week 28 the following markers will be assessed: Free fatty acid serum profile, sThy-1, adiponectin, leptin, insulin, HOMA-IR, proinsulin, IL-6, TNF-alpha, M30 assay, IL-1 beta, IL-1Ra, IL-18, IL-18bp, P1NP, CTX, RANKL, OPG, sclerostin, NT-proBNP, CD154, and a 30-panel multiplex inflammatory cytokine and chemokines panel |
|
E.3 | Principal inclusion criteria |
1. Written informed consent must be obtained before any assessment is performed.
2. Men or women of at least 18 years of age at the time of screening.
3. Patients with moderate to severe plaque-type psoriasis who are candidates for systemic therapy.
4. Fulfillment of metabolic syndrome diagnosis criteria at screening visit.
5. Willingness and motivation to actively participate in the lifestyle intervention, which means patients need to be willing to increase physical activity and to change dietary habits in order to achieve weight loss. |
|
E.4 | Principal exclusion criteria |
1. Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and guttate psoriasis) at screening.
2. Previous exposure to Secukinumab or any other biologic drug directly targeting IL17A or the IL17A receptor (e.g. Brodalumab, Ixekizumab).
3. History of hypersensitivity to Secukinumab, trehalose-dihydrate, L-histidine, L-histidinhydrochloride-monohydrate, L-methionine, polysorbate 80, water for injection, or to substances of similar chemical classes.
4. Diagnosis of type 1 diabetes.
5. Significant, progressive or uncontrolled medical problems at baseline which according to the opinion of the Investigator render the subject unsuitable for the trial - also in regard to participation in the lifestyle intervention - or put the subject at increased risk when participating in the trial. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Percentage of patients achieving PASI90 at week 28 in both randomized treatment arms, Secukinumab alone and Secukinumab combined with lifestyle intervention |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
- PASI75, 90 and 100 as well as absolute PASI scores in both treatment arms at week 1, 2, 3, 4, 8, 12, 16, 20, 24 and 28
- hsCRP in both treatment arms throughout the duration of the core study
- HbA1c, fructosamine and fasting plasma glucose in both treatment arms throughout the duration of the core study
- Total cholesterol, LDL, HDL and triglycerides in both treatment arms throughout the duration of the core study
- Waist circumference, body weight and BMI in both treatment arms throughout the duration of the core study
- Systolic and diastolic blood pressure in both treatment arms throughout the duration of the core study
- Absolute DLQI, relative change of DLQI, proportion of patients withDLQI 0/1, absolute WHO-5, relative change in WHO-5, absolute self-assessed itch, pain, scaling, relative change in self-assessed itch, pain, scaling in both treatment arms throughout the duration of the core study |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Synergistic effect of lifestyle intervention |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 68 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 1 |
E.8.9.1 | In the Member State concerned days | 15 |